STAT - Reporting from the frontiers of health and medicine

Health

Politics

First Opinion

By Karla Theilen

Pharma In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment
Health Tech 5 companies harnessing AI for drug discovery to watch
First Opinion Next steps for wastewater testing to help end this pandemic — and prevent the next one
First Opinion Podcast Listen: Priscilla Chan on pediatric biology and research: ‘Children are not tiny adults’
Politics Bipartisan pair of senators calls on Congress to examine expensive new Alzheimer’s drug

Daily, market-moving coverage of biotech and pharma

Inside intelligence on the NIH, the FDA, and Congress

Profiles of the power players shaping the industry

Analysis of the latest scientific developments

Arcus’ anti-TIGIT immunotherapy shows ‘encouraging’ tumor response, but likely leaves investors wanting more
Teva agrees to pay $925,000 to Mississippi to settle generic price-fixing charges
Pharmalittle: Lilly seeks speedy U.S. approval for its Alzheimer’s drug; FDA’s Woodcock ‘not concerned’ about criticism

Special Report

Health

Heavyweights

Health

Prescription Politics

Special Report

Health Officials note ‘likely association’ between Covid-19 vaccines and rare heart condition in young people
Health Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson
Special Report The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race
Pharma In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment
Politics FDA’s Woodcock is just ‘not that concerned’ about the criticism over Biogen’s Alzheimer’s drug, Aduhelm
Health A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?
Health The Covid-19 Tracker
Health Tech 5 companies harnessing AI for drug discovery to watch